The primary objective of the study is to evaluate the adherence to the treatment with interferon beta-1b, in patients diagnosed with isolated syndrome (CIS), relapsing-remitting multiple sclerosis (RRMS), or secondary progressive multiple sclerosis (SPMS) who had more than 6 months in treatment.
Study Type
OBSERVATIONAL
Enrollment
120
Interferon beta-1b (INFb-1b) was used at the standard dose of 250 mg/ml.
Self-reported adherence to INFb-1b in the previous four weeks assessed by Morisky-Green (MG) test
Time frame: Four weeks just before baseline visit
Demographic data
Age, sex, marital status, education level, employment status
Time frame: At baseline
Number of patients with MS diagnosis
Time frame: At baseline
Age at first episode and at diagnosis
Time frame: At baseline
Time since last relapse
Time frame: At baseline
Assessment of general health status using data from a questionnaire or from their clinical history collected by the investigator team
Time frame: At baseline
Expanded Disability Status Scale (EDSS) to assess the degree of disability caused by MS
The EDSS quantifies the disability in eight functional systems (FS) and allows neurologists to assign a level of Functional System in each of them caused by multiple sclerosis.
Time frame: At baseline
Number of patients with adverse events during the last month
Time frame: Four weeks just before baseline visit
Clinical setting characteristics like existence of MS unit
The existence of Multiple Sclerosis Unit was evaluated bearing in mind if the hospital had or had not available a Multiple Sclerosis Unit into the hospital Neurology Department.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: At baseline
Time on INFb-1b therapy
Time frame: At baseline